On a reported basis, net income attributable to Medtronic was
$1.17 billion, or $0.87 per share, compared to $1.46 billion, or $1.07 per
share. Adjusted net income was $2.07 billion, or $1.54 per share.
Revenue in the US grew 2.3% year-over-year to $4.2 billion. Non-US
developed market revenue totaled $2.5 billion, down 5.3% on a reported basis
and up 1.7% on a constant currency basis. Revenue from emerging markets amounted
to $1.28 billion, reflecting a growth of 3.9% on a reported basis and 12% on a
constant currency basis.
In the Cardiac and Vascular Group division, revenues fell
2.7% on a reported basis and rose 1.1% in constant currency. In the Minimally
Invasive Therapies Group, revenue increased 0.8% on a reported basis and 5.1%
on a constant currency basis.
In the Restorative Therapies Group, revenues increased 4.1%
as reported and 6.5% in constant currency. In the Diabetes Group, revenue fell
2.9% as reported but grew 0.6% in constant currency.
For fiscal year 2020, organic revenue is expected to grow 4%.
Adjusted EPS is expected to be $5.44 to $5.50.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.